Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Dermatology > WCD 2023 > Hair Disorders > Can ritlecitinib deliver long-term efficacy in alopecia areata?

Can ritlecitinib deliver long-term efficacy in alopecia areata?

Presented by
Prof. Melissa Piliang, Cleveland Clinic, OH, USA
Conference
WCD 2023
Trial
Phase 3, ALLEGRO
Doi
https://doi.org/10.55788/de921e89

    The efficacy of ritlecitinib as a therapy for patients with alopecia areata (AA) continued to increase over 2 years of follow-up of the ALLEGRO trials. Importantly, the agent was well tolerated in the long term. The long-term trial is ongoing and further results are expected in the future.

    Prof. Melissa Piliang (Cleveland Clinic, OH, USA) presented the efficacy results from a pooled analysis of the pivotal phase 2b/3 ALLEGRO trial (NCT03732807) and the ALLEGRO-LT trial (NCT04006457) [1]. In total, 502 participants with AA received a 200 mg loading dose of ritlecitinib for 4 weeks followed by a daily dose of 50 mg, and 191 participants received 50 mg daily, without the loading dose.

    After 24 months of therapy, 58.4% of the participants in the loading-dose arm and 61.6% of the non-loading-dose arm achieved a Severity of Alopecia Tool (SALT) score ≤20 (see Figure). Prof. Piliang clarified that the initial advantage in response rate of the 200 mg loading-dose group was no longer present at 24 months of follow-up. “At 12 months, we observed response rates of 52.2% in the 200/50 mg arm and 45.1% in the 50 mg arm. These rates continued to increase in the following year and turned out to be similar at 24 months.” Furthermore, a SALT score ≤10 was reached by 47.2% and 51.2% of the participants in the 200/50 mg arm and 50 mg arm, respectively.

    Figure: The proportion of patients with SALT score ≤20 and ≤10 up to month 24 [1]

    CI, confidence interval; SALT, Severity of Alopecia Tool.

    The most common adverse events were headache (15.2–15.5%), SARS-CoV-2-positivity (12.2–14.7%), nasopharyngitis (11.0–11.2%), and acne (10.4–11.5%). Herpes simplex was seen in 2% of the participants and herpes zoster was reported in 1.2–3.7% of the participants.

    “These results demonstrate the clinically meaningful and sustained long-term efficacy of ritlecitinib in patients with AA,” concluded Prof. Piliang.




    1. Piliang M, et al. Long-term efficacy of ritlecitinib up to month 24: integrated analysis of the ALLEGRO phase 2b/3 and long-term phase 3 clinical studies in alopecia areata (AA). Late-breaker Session 3, WCD 2023, 3–8 July, Singapore, Singapore.
    Copyright ©2023 Medicom Medical Publishers




    Posted on